Honkanen 2004.

Methods	computer generated random sequence; packing company prepared bags containing the medication according to the randomisation sequence
Participants	2219 women; mean age 27 years; </= 63 days of amenorrhoea; Inclusion criteria:single intrauterine pregnancies, haemoglobin > 100 g/L . Exclusion criteria: medical contraindications or allergy for either mifepristone or misoprostol; past or present thromboembolism; liver disease, pruritus of pregnancy; previous surgery of uterine cervix; presence of an intrauterine device; suspected or proven ectopic pregnancy; smoking > 10 cigarettes/day; risk factor for cardiovascular disease; breastfeeding; Study was conducted from October 1998 ‐ Decembre 2000 in 15 cities in 11 countries, including developed and developing countries: Beijing, Hong Kong and Shanghai ‐ China; Chandigarh, Mumbai and New Delhi ‐ India; Helsinki ‐ Finland; Ho Chi Minh City ‐ Viet Nam; Ljubljana ‐Slovenia; Oslo ‐ Norway; Singapore ‐ Singapore; Stockholm ‐ Sweden; Szeged ‐ Hungary; Targu Mures ‐ Romania; and Ulaanbaatar ‐ Mongolia.
Interventions	mifepristone 200mg followed 36‐48 hours later by: group 1: misoprostol 800mcg orally followed by misoprostol 400mcg twice/day for 6 days oral group 2: misoprostol 800mcg vaginally followed by misoprostol 400mcg twice/day for 6 days oral group 3: misoprostol 800mcg vaginally followed by placebo tablets twice/day for 6 days oral
Outcomes	side‐effects and acceptability
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Low risk	A ‐ adequate